Zobrazeno 1 - 10
of 101
pro vyhledávání: '"SUMIYOSHI, YOSHITERU"'
Autor:
Ohno, Satoshi, Sumiyoshi, Yoshiteru, Hashine, Katsuyoshi, Shirato, Akitomi, Kyo, Satoru, Inoue, Masaki
Publikováno v:
In Complementary Therapies in Medicine October 2013 21(5):460-467
Autor:
Kakehi, Yoshiyuki, Kamoto, Toshiyuki, Shiraishi, Taizo, Kato, Tetsuro, Tobisu, Ken-ichi, Akakura, Koichiro, Egawa, Shin, Maeda, Osamu, Sumiyoshi, Yoshiteru, Arai, Yoichi, Ogawa, Osamu
Publikováno v:
In European Urology January 2002 41(1):47-53
Autor:
YOSHIMURA, KOJI1, SUMIYOSHI, YOSHITERU2, HASHIMURA, TAKAYUKI3, UEDA, TOMOHIRO4, KAMIRYO, YORIAKI5, YAMAMOTO, AKIHIRO6, ARAI, YOICHI7
Publikováno v:
International Journal of Urology. Apr2003, Vol. 10 Issue 4, p190-195. 6p.
Autor:
Sumiyoshi, Yoshiteru1, Hashine, Katsuyoshi1, Nakatsuzi, Hironori1, Yamashita, Yokihiko1, Karashima, Takashi1
Publikováno v:
International Journal of Urology. Jul2000, Vol. 7 Issue 7, p243-247. 5p.
Autor:
Akakura, Koichiro *, Isaka, Shigeo, Akimoto, Susumu, Ito, Haruo, Okada, Kiyoki, Hachiya, Takahiko, Yoshida, Osamu, Arai, Yoichi, Usami, Michiyuki, Kotake, Toshihiko, Tobisu, Ken-Ichi, Ohashi, Yasuo, Sumiyoshi, Yoshiteru, Kakizoe, Tadao, Shimazaki, Jun
Publikováno v:
In Urology 1999 54(2):313-318
Publikováno v:
泌尿器科紀要. 53(2):93-97
Between April 2004 and August 2005, we used docetaxel in combination with prednisolone to treat 14 patients with hormone-refractory prostate cancer (HRPC). Docetaxel was administered at a dose of 70 mg/m2 once every 21 days and oral prednisolone 5 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::fc9c97a17b9d95208e4d9e0ead55c153
http://hdl.handle.net/2433/71353
http://hdl.handle.net/2433/71353
Autor:
Numata, Kousaku, Miura, Noriyoshi, Azuma, Koji, Karashima, Takashi, Kasahara, Kotaro, Nakatsuzi, Hironori, Hashine, Katsuyoshi, Sumiyoshi, Yoshiteru
Publikováno v:
泌尿器科紀要. 53(2):99-104
A total of 42 patients with hormone-refractory prostate cancer received E-E therapy. Oral estramustine phosphate (EMP) was administered twice daily for a total daily dose of 560 mg every day and oral etoposide (E-E therapy, 50 mg/body/day) was given
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::9cbaa572bbeecebacc761072f25c7bd7
http://hdl.handle.net/2433/71352
http://hdl.handle.net/2433/71352
Publikováno v:
泌尿器科紀要. 45(11):745-748
根治的膀胱全摘除術や動注化学放射線療法が施行できない浸潤性膀胱癌に対して, 白金製剤を用いた全身化学放射線併用療法を行い, 8例中6例のCRが得られ, 有害事象に関しても寛容であっ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::11e8c62d7a533a022fbfc23e1d8f5ebc
http://hdl.handle.net/2433/114164
http://hdl.handle.net/2433/114164
Autor:
NAKATSUJI, Hiroyoshi, YAMASHITA, Yokihiko, KARASHIMA, Takashi, HASHINE, Katsuyoshi, SUMIYOSHI, Yoshiteru
Publikováno v:
泌尿器科紀要. 45(10):695-698
症例1(68歳男)は上咽頭癌の既往があり, 胃癌精査中に右腎下極に径20mm, 左腎中外側部に径20mmの腎癌を発見され, 胃部分切除と両側腎部分切除を行った.術後43ヵ月目に肺炎で死亡し, 腎癌の
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::7de67d2979632ecd32e04abf7bf674e6
http://hdl.handle.net/2433/114141
http://hdl.handle.net/2433/114141
Publikováno v:
泌尿器科紀要. 45(2):155-158
浸潤性膀胱癌に対する放射線併用動注化学療法のretrospective studyの長期成績及び現在施行中のprospective studyについて報告した.この治療により膀胱温存が可能な症例や治療法を考察した.前
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::885504f264a9d0b2d307b70146d656a3
http://hdl.handle.net/2433/113977
http://hdl.handle.net/2433/113977